Selective KIT Inhibitor KI-328 and HSP90 Inhibitor Show Different Potency Against the Type of KIT Mutations Recurrently Identified in Acute Myeloid Leukemia

Overview

Journal Int J Hematol

Specialty Hematology

Date 2010 Oct 5

PMID 20890793

Citations 2

Authors

Akane Tsujimura

Hitoshi Kiyoi

Yukimasa Shiotsu

Yuichi Ishikawa

Yumiko Mori

Hiroshi Ishida

Tsutomu Toki

Etsuro Ito

Tomoki Naoe

Affiliations

Soon will be listed here.

Abstract

Activating mutations of KIT play an important role in the pathophysiology of several human malignancies, including acute myeloid leukemia. Activated KIT kinase is therefore a promising molecular target for the treatment of many malignancies harboring KIT activation. Here we examined the potency of a novel KIT inhibitor KI-328 against different types of mutant KIT kinases recurrently identified in AML. KI-328 shows selective potency against KIT kinase for the in vitro kinase assay, and inhibits the growth of wild-type (Wt)- and mutant-KIT-expressing cells, while it has little potency against D816V-KIT. Comparable analysis of several potent KIT inhibitors regarding growth inhibitory effects on a variety of mutant-KIT-expressing cells revealed that multi-kinase inhibitors have the same potency against D816V-KIT as other mutant KITs; however, the predominant potency against D816V-KIT was observed in heat shock protein 90 (HSP90) inhibitors. Furthermore, HSP90 inhibitors suppress the growth of D816V-KIT-expressing cells at the concentration at which the growth of other mutant-KIT-expressing cells is not affected. These results collectively indicated that potent KIT inhibitors have different potency against the type of mutant KIT kinases. Therefore, KIT inhibitors are required to validate potency against several types of mutant KIT kinases for the clinical development.

Citing Articles

Sustained inhibition of CSF1R signaling augments antitumor immunity through inhibiting tumor-associated macrophages.

Sato T, Sugiyama D, Koseki J, Kojima Y, Hattori S, Sone K JCI Insight. 2025; 10(1.

PMID: 39782686 PMC: 11721313. DOI: 10.1172/jci.insight.178146.

Mutated KIT Tyrosine Kinase as a Novel Molecular Target in Acute Myeloid Leukemia.

Katagiri S, Chi S, Minami Y, Fukushima K, Shibayama H, Hosono N Int J Mol Sci. 2022; 23(9).

PMID: 35563085 PMC: 9103326. DOI: 10.3390/ijms23094694.

miR-145 Antagonizes SNAI1-Mediated Stemness and Radiation Resistance in Colorectal Cancer.

Zhu Y, Wang C, Becker S, Hurst K, Nogueira L, Findlay V Mol Ther. 2018; 26(3):744-754.

PMID: 29475734 PMC: 5910672. DOI: 10.1016/j.ymthe.2017.12.023.

References

Whitesell L, Lindquist S . HSP90 and the chaperoning of cancer. Nat Rev Cancer. 2005; 5(10):761-72. DOI: 10.1038/nrc1716. View

Yarden Y, Kuang W, Coussens L, MUNEMITSU S, Dull T, Chen E . Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J. 1987; 6(11):3341-51. PMC: 553789. DOI: 10.1002/j.1460-2075.1987.tb02655.x. View

Roskoski Jr R . Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor. Biochem Biophys Res Commun. 2005; 338(3):1307-15. DOI: 10.1016/j.bbrc.2005.09.150. View

Paschka P, Marcucci G, Ruppert A, Mrozek K, Chen H, Kittles R . Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol. 2006; 24(24):3904-11. DOI: 10.1200/JCO.2006.06.9500. View

Foster R, Byrnes E, Meldrum C, Griffith R, Ross G, Upjohn E . Association of paediatric mastocytosis with a polymorphism resulting in an amino acid substitution (M541L) in the transmembrane domain of c-KIT. Br J Dermatol. 2008; 159(5):1160-9. DOI: 10.1111/j.1365-2133.2008.08827.x. View

Schnittger S, Kohl T, Haferlach T, Kern W, Hiddemann W, Spiekermann K . KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival. Blood. 2005; 107(5):1791-9. DOI: 10.1182/blood-2005-04-1466. View

Zhao M, Kiyoi H, Yamamoto Y, Ito M, Towatari M, Omura S . In vivo treatment of mutant FLT3-transformed murine leukemia with a tyrosine kinase inhibitor. Leukemia. 2000; 14(3):374-8. DOI: 10.1038/sj.leu.2401680. View

Cairoli R, Beghini A, Grillo G, Nadali G, Elice F, Ripamonti C . Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. Blood. 2005; 107(9):3463-8. DOI: 10.1182/blood-2005-09-3640. View

Kiyoi H, Shiotsu Y, Ozeki K, Yamaji S, Kosugi H, Umehara H . A novel FLT3 inhibitor FI-700 selectively suppresses the growth of leukemia cells with FLT3 mutations. Clin Cancer Res. 2007; 13(15 Pt 1):4575-82. DOI: 10.1158/1078-0432.CCR-07-0225. View

10.

Bauer S, Yu L, Demetri G, Fletcher J . Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor. Cancer Res. 2006; 66(18):9153-61. DOI: 10.1158/0008-5472.CAN-06-0165. View

11.

Wandinger S, Richter K, Buchner J . The Hsp90 chaperone machinery. J Biol Chem. 2008; 283(27):18473-7. DOI: 10.1074/jbc.R800007200. View

12.

Dubreuil P, Letard S, Ciufolini M, Gros L, Humbert M, Casteran N . Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT. PLoS One. 2009; 4(9):e7258. PMC: 2746281. DOI: 10.1371/journal.pone.0007258. View

13.

Gotlib J, Berube C, Growney J, Chen C, George T, Williams C . Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood. 2005; 106(8):2865-70. PMC: 1895309. DOI: 10.1182/blood-2005-04-1568. View

14.

Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S . Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998; 279(5350):577-80. DOI: 10.1126/science.279.5350.577. View

15.

Pan J, Quintas-Cardama A, Kantarjian H, Akin C, Manshouri T, Lamb P . EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation. Blood. 2006; 109(1):315-22. DOI: 10.1182/blood-2006-04-013805. View

16.

Corbin A, Griswold I, La Rosee P, Yee K, Heinrich M, Reimer C . Sensitivity of oncogenic KIT mutants to the kinase inhibitors MLN518 and PD180970. Blood. 2004; 104(12):3754-7. DOI: 10.1182/blood-2004-06-2189. View

17.

Ishikawa Y, Kiyoi H, Tsujimura A, Miyawaki S, Miyazaki Y, Kuriyama K . Comprehensive analysis of cooperative gene mutations between class I and class II in de novo acute myeloid leukemia. Eur J Haematol. 2009; 83(2):90-8. DOI: 10.1111/j.1600-0609.2009.01261.x. View

18.

Shah N, Tran C, Lee F, Chen P, Norris D, Sawyers C . Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004; 305(5682):399-401. DOI: 10.1126/science.1099480. View

19.

Lennartsson J, Jelacic T, Linnekin D, Shivakrupa R . Normal and oncogenic forms of the receptor tyrosine kinase kit. Stem Cells. 2004; 23(1):16-43. DOI: 10.1634/stemcells.2004-0117. View

20.

Abrams T, Lee L, Murray L, Pryer N, Cherrington J . SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther. 2003; 2(5):471-8. View